A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

277

Enrollment

INDUSTRY

Sponsor class

Conditions

Eosinophilic Esophagitis

Interventions

OTHER: Placebo
DRUG: lirentelimab (AK002)

Sponsor

Allakos Inc.